Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Zhaoke Ophthalmology Ltd. has secured marketing authorizations from China’s National Medical Products Administration for three new glaucoma drugs, expanding its comprehensive product portfolio for intraocular pressure management. With these additions, including Latanoprost, Travoprost, and Travoprost Timolol eye drops, the company aims to offer a broader selection for treating glaucoma patients in China, where the condition is highly prevalent. This development positions Zhaoke Ophthalmology to better serve the growing demand in the Chinese market.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue